Clinquest Group and TNO sign licensing agreement on protein for inflammatory disorders
Clinquest obtains exclusive worldwide rights to clinical development and commercialization
CQ-07001 is an endogenous human protein that has shown to be a powerful agonist to Toll-Like Receptor 3 (TLR 3). The 10 human Toll-Like Receptors (TLR) are generally implicated in recognizing pathogens and inducing immune responses and as such, TLRs play in important role in maintaining the body's capacity to counter harmful invaders. Studies performed by TNO have shown that TLR 3, in contrast to the other TLRs, is stimulated by CQ-07001 and subsequently triggers anti-inflammatory and tissue repair responses. This capacity of CQ-07001 makes it a promising candidate for clinical development aimed at various anti-inflammatory and tissue regeneration applications - both fields offer large market potential.
Most read news
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.